Publications
300 publications
Sort by: Date / Relevance
GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups
Zorginstituut Nederland has completed its assessment whether 13-valent pneumococcal conjugate vaccine (PVC13; Prevenar13®) is ...
GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Zorginstituut Nederland has completed its assessment whether Brimonidine Stulln 2mg/ml eye drop solution, single-use packaging is ...
GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia
Zorginstituut Nederland has completed its assessment whether sodium zirconium cyclosilicate (Lokelma®) is interchangeable with a ...
Package advice multiple myeloma
Several combination therapies that are used to treat multiple myelomain are placed in the lock procedure for expensive medicinal ...
GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease
Zorginstituut Nederland has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product that has ...
GVS advice mexiletine (Namuscla®)
Zorginstituut Nederland has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable with another ...
GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
Zorginstituut Nederland has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product that is ...
GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...
GVS assessment - extension of further conditions for nintedanib (Ofev®)
Zorginstituut Nederland has completed its assessment of the possible extension of the further conditions for nintedanib (Ofev®) ...
Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...